Prognostic Value ofl8F-FDG PET in patients with head and neck squamous cell cancer

American Journal of Roentgenology

Volumn 192, Issue 4, 2009, Pages

  Torizuka, Tatsuo ^a,b   Tanizaki, Yasuo ^a   Kanno, Toshihiko ^a   Futatsubashi, Masami ^c   Naitou, Katsumi ^a   Ueda, Yo ^a   Ouchi, Yasuomi ^a  

^a HAMAMATSU MEDICAL CENTER   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HAMAMATSU PHOTONICS K K   (Japan)

Author keywords

FDG PET; Head and neck cancer; Prognosis; Standardized uptake value

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; SHR22000; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; MALE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; CANCER STAGING; HEAD AND NECK TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SCINTISCANNING; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS;

EID: 63849130556     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.08.1429     Document Type: Article

References (18)

1. Garden AS, Asper JA, Morrison WH, et al. Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma? Cancer 2004; 100:1171-1178
2. Lydiatt WM, Shah JP, Hoffman HT; Head and Neck Sites Task Force; American Joint Committee on Cancer. AJCC stage groupings for head and neck cancer: should we look at alternatives? A report of the Head and Neck Sites Task Force. Head Neck 2001; 23:607-612
3. Chang JT, Chan SC, Yen TC, et al. Nasopharyngeal carcinoma staging by(18)F-fluorodeoxyglu-cose positron emission tomography. Int J Radiat Oncol Biol Phys 2005; 62:501-507
4. Goerres GW, Schmid DT, Gratz KW, von Schulthess GK, Eyrich GK. Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 2003; 39:547-551
5. Haberkorn U, Strauss LG, Reisser C, et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991; 32:1548-1555
6. Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-me thionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1995; 36:252-258
7. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition(1997): Union Internationale Contre le Cancer and the America Joint Committee on Cancer. Cancer 1997; 80:1803-1804
8. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lym-phoma. Eur J Nucl Med Mol Imaging 2004; 31:22-28
9. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235-238
10. Tian M, Zhang H, Higuchi T, et al. Hexokinase-II expression in untreated oral squamous cell carcinoma: comparison with FDG PET imaging. Ann Nucl Med 2005; 19:335-338
11. Kunkel M, Reichert TE, Benz P, et al. Overex-pression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003; 97:1015-1024
12. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997; 38:1907-1911
13. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET: a possible prognostic factor in head and neck cancer. Br J Cancer 2002; 86:512-516
14. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[(18)F] fluoro-2-de-oxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20:1398-1404
15. 18F]fluoro-2-deoxy- D-glucose. Int J Radiat Oncol Biol Phys 2004; 59:1295-1300
16. 18)F]fluorodeoxyglu-cose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20:4199-4208
17. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004; 130:1361-1367
18. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995; 196:167-173